微小RNA与癌症耐药性:两千余字探寻其作用

MicroRNAs and cancer drug resistance: over two thousand characters in search of a role.

作者信息

Gomes Bruno Costa, Rueff José, Rodrigues António Sebastião

机构信息

Centre for Toxicogenomics and Human Health; Genetics, Oncology and Human Toxicology, NOVA Medical School, Universidade Nova de Lisboa, Lisboa 1150-008, Portugal.

出版信息

Cancer Drug Resist. 2019 Sep 19;2(3):618-633. doi: 10.20517/cdr.2019.55. eCollection 2019.

Abstract

MicroRNAs (miRNAs), a group of small regulatory noncoding RNAs, transformed our thinking on gene regulation. More than two thousand human miRNAs have been identified thus far. These bind imperfectly to the 3'-untranslated region of target mRNA and have been involved in several pathological conditions including cancer. In fact, major hallmarks of cancer, such as the cell cycle, cell proliferation, survival and invasion are modulated by miRNAs. Cancer drug resistance (CDR) has also been described as being modulated by miRNAs. CDR remains a burden for cancer therapy and patients' outcome, often resulting in more aggressive tumours that tend to metastasize to distant organs. In this review we discuss the role of miRNAs influencing drug metabolism and drug influx/efflux, two important mechanisms of CDR.

摘要

微小RNA(miRNA)是一类小的调节性非编码RNA,改变了我们对基因调控的看法。迄今为止,已鉴定出两千多种人类miRNA。它们与靶mRNA的3'非翻译区不完全结合,并参与了包括癌症在内的多种病理状况。事实上,癌症的主要特征,如细胞周期、细胞增殖、存活和侵袭,都受到miRNA的调控。癌症耐药性(CDR)也被描述为受miRNA调控。CDR仍然是癌症治疗和患者预后的负担,常常导致更具侵袭性的肿瘤,这些肿瘤往往会转移到远处器官。在这篇综述中,我们讨论了miRNA在影响药物代谢以及药物流入/流出方面的作用,这是CDR的两个重要机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d7b/8992528/aba62b76e1e0/cdr-2-618.fig.1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索